Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $105.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 77.54% from the stock’s current price. A […]
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a.
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 52-Week High at $66 57 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 77.54% from the stock’s current price. A number […]
Shares of Praxis Precision Medicines, Inc. (PRAX) jumped over 26% on Tuesday morning after the company reported positive results from a phase 2 study of epilepsy treatment.